by Charlie Perrecone | Jul 17, 2013
Forbes.com Matthew Herper describes the distorted image of the director of the FDA’s Oncology and Hematology Products, Dr. Richard Pazdur, as the villain to cancer treatments by his critics. In an interview he gave at the annual American Society of Clinical Oncology,...
by Charlie Perrecone | Jul 12, 2013
On August 8, 2013, Gretchen Bowker, co-founder and COO of Pearl Pathways, will host a webinar on ComplianceOnline.com reviewing the similarities and differences in the regulatory paths and requirements for drugs, biologics and medical devices. It will discuss the...
by Charlie Perrecone | Jul 12, 2013
Do you work at a site as a clinical research coordinator and need a deeper dive into Good Clinical Practices (GCPs)? Are you a sponsor who has responsibility for oversight and training of site personnel? On July 26, 2013, Pearl Pathways’ own Ellen Looney will lead a...
by Charlie Perrecone | Jul 12, 2013
Are you a supplier of raw materials, component parts or finished product to biopharma or medical device companies? The supply chain for pharmaceuticals, biologics and medical device companies are increasingly being audited by their clients and FDA. On July 25, 2013,...
by Charlie Perrecone | Jul 9, 2013
Kyle Alspach shares on bizjournals.com that there was biotech boom of venture capital (VC) backed IPOs during the second quarter of 2013. Out of the 21 IPOs funded by VCs, thirteen were categorized as life science related and eleven of those thirteen were biotech. Two...
